Clay Siegall
Clay Siegall founded Seattle Genetics in 1998 and served as the CEO of the firm. Seattle Genetics is a registered biotech firm which is widely known in the field of target cancer therapies. Under the administration of Clay Siegall, Seattle Genetics produced a remarkable product in the fight against cancer known as conjugate or ADC. It was approved by the FDA and is currently used as an effective intervention against cancer.
Clay Siegall has been on the forefront to fight against cancer for two decades. He supports groups and organizations that fight against this deadly disease. Apart from leading Seattle Genetics, Dr. Clay Siegall also sits on the board of directors in the following organizations; committees of director of Ultragenyx Pharmaceutical, Mirna Therapeutics, Inc., and Alder Bio-pharmaceuticals. He obtained his bachelor’s degree in zoology then advanced his studies and was granted a PhD in Genetics. This makes him one of the most qualified individuals in this field.
Apart from the leadership roles, Clay Siegall is a community leader who offers humanitarian services. He has dedicated his time and resources to patients who cannot afford cancer treatment. Moreover, he provides support to charitable organizations that are involved in helping cancer patients.
In this article Clay Siegall talks about the efforts that have been put in place by researchers in fighting cancer.
The Fight Against Cancer
Cancer claims the lives of approximately 600,000 individuals in the United States annually. Given these statistics, cancer is mostly regarded as a significant cause of deaths. However, these numbers will continue to reduce given the endless work by the researchers, institutes, and universities in fighting against cancer. By strengthening the target therapy interventions, cancer will reduce its effect, and only a few lives will be lost compared to the present state.
Clay Siegall focuses his attention on the new intervention by a group of researchers in the Netherlands. They were able to come up with a method for early diagnosis of prostate cancer. Early diagnosis will make prostate cancer treatable. Other interventions include the use of genome sequencing to test for cancer by Prof Dame Sally Davies. Increase in this interventions will have a significant impact on cancer diagnosis and treatment.